Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1960 2
1961 1
1962 2
1965 1
1967 2
1968 1
1969 6
1974 1
1975 7
1976 11
1977 3
1978 4
1979 3
1980 2
1981 9
1982 8
1983 12
1984 13
1985 13
1986 9
1987 11
1988 7
1989 11
1990 17
1991 14
1992 15
1993 15
1994 23
1995 29
1996 21
1997 15
1998 10
1999 19
2000 17
2001 20
2002 21
2003 31
2004 22
2005 24
2006 18
2007 19
2008 28
2009 32
2010 33
2011 35
2012 40
2013 32
2014 44
2015 39
2016 32
2017 43
2018 44
2019 39
2020 44
2021 36
2022 31
2023 38
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

1,007 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: izumi h. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. Among authors: izumi h. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.
Neuroblastoma.
Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Nakagawara A, et al. Among authors: izumi h. Jpn J Clin Oncol. 2018 Mar 1;48(3):214-241. doi: 10.1093/jjco/hyx176. Jpn J Clin Oncol. 2018. PMID: 29378002 Review.
Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
Kashima Y, Shibahara D, Suzuki A, Muto K, Kobayashi IS, Plotnick D, Udagawa H, Izumi H, Shibata Y, Tanaka K, Fujii M, Ohashi A, Seki M, Goto K, Tsuchihara K, Suzuki Y, Kobayashi SS. Kashima Y, et al. Among authors: izumi h. Cancer Res. 2021 Sep 15;81(18):4835-4848. doi: 10.1158/0008-5472.CAN-20-2811. Epub 2021 Jul 9. Cancer Res. 2021. PMID: 34247147 Free PMC article.
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, Nishino K, Nakachi I, Kuyama S, Daga H, Hara S, Miyamoto S, Kato T, Sakakibara-Konishi J, Tabata E, Nakagawa T, Kawaguchi T, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Yoh K, Goto K. Sugimoto A, et al. Among authors: izumi h. Clin Cancer Res. 2023 Apr 14;29(8):1506-1514. doi: 10.1158/1078-0432.CCR-22-1749. Clin Cancer Res. 2023. PMID: 36201167
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. Izumi H, et al. Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24. Nature. 2021. PMID: 34819663 Free PMC article.
Lung disorders induced by respirable organic chemicals.
Morimoto Y, Nishida C, Tomonaga T, Izumi H, Yatera K, Sakurai K, Kim Y. Morimoto Y, et al. Among authors: izumi h. J Occup Health. 2021 Jan;63(1):e12240. doi: 10.1002/1348-9585.12240. J Occup Health. 2021. PMID: 34128301 Free PMC article. Review.
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma.
Tanaka Y, Nakai T, Suzuki A, Kagawa Y, Noritake O, Taki T, Hashimoto H, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanbe R, Tsuboi M, Goto K, Ishii G. Tanaka Y, et al. Among authors: izumi h. Cancer Immunol Immunother. 2023 Jul;72(7):2205-2215. doi: 10.1007/s00262-023-03393-8. Epub 2023 Mar 2. Cancer Immunol Immunother. 2023. PMID: 36862151 Review.
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. Qin Z, et al. Among authors: izumi h. J Exp Med. 2024 Mar 4;221(3):e20232028. doi: 10.1084/jem.20232028. Epub 2024 Jan 29. J Exp Med. 2024. PMID: 38284990
1,007 results